Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EPRXNASDAQ:FTLFNASDAQ:PLURNASDAQ:TIL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEPRXEupraxia Pharmaceuticals$3.94+1.5%$3.60$2.20▼$4.48$141.25MN/A13,155 shs23,072 shsFTLFFitLife Brands$14.81+1.2%$13.63$9.83▼$17.75$137.49M0.918,072 shs5,508 shsPLURPluri$4.47+0.2%$4.60$3.33▼$7.13$35.01M0.7715,927 shs11,606 shsTILInstil Bio$29.65+10.0%$16.77$9.62▼$92.00$194.47M1.78158,840 shs1.22 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEPRXEupraxia Pharmaceuticals+0.25%+1.81%-1.62%+9.14%+45.39%FTLFFitLife Brands-0.20%+1.58%-6.03%-0.87%-3.49%PLURPluri+0.22%-1.97%-8.59%+0.68%-27.32%TILInstil Bio+13.69%+41.06%+104.77%+69.43%+177.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEPRXEupraxia Pharmaceuticals2.1383 of 5 stars3.71.00.00.02.40.00.6FTLFFitLife Brands4.5736 of 5 stars3.75.00.00.03.03.33.1PLURPluri1.8086 of 5 stars3.53.00.00.01.80.80.0TILInstil Bio3.5172 of 5 stars3.54.00.00.02.23.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEPRXEupraxia Pharmaceuticals 3.33Buy$10.50166.50% UpsideFTLFFitLife Brands 3.33Buy$20.5038.42% UpsidePLURPluri 3.00Buy$12.00168.46% UpsideTILInstil Bio 3.00Buy$112.33278.86% UpsideCurrent Analyst Ratings BreakdownLatest PLUR, EPRX, TIL, and FTLF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025PLURPluriAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/2/2025TILInstil BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/22/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$110.00 ➝ $105.003/17/2025FTLFFitLife BrandsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.003/5/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$110.00 ➝ $110.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEPRXEupraxia PharmaceuticalsN/AN/AN/AN/A$0.03 per shareN/AFTLFFitLife Brands$63.86M2.18$0.78 per share19.05$3.04 per share4.87PLURPluri$1.03M33.86N/AN/A($0.42) per share-10.64TILInstil BioN/AN/AN/AN/A$34.72 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEPRXEupraxia Pharmaceuticals-$28.22M-$0.76N/AN/AN/AN/A-219.64%-96.00%8/6/2025 (Estimated)FTLFFitLife Brands$5.30M$0.8417.5313.46N/A13.38%28.03%15.13%N/APLURPluri-$20.89M-$5.53N/A∞N/A-3,551.49%-2,778.13%-83.61%N/ATILInstil Bio-$156.09M-$11.97N/AN/AN/AN/A-37.44%-25.08%8/12/2025 (Estimated)Latest PLUR, EPRX, TIL, and FTLF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025FTLFFitLife Brands$0.24$0.20-$0.04$0.20N/AN/A5/13/2025Q3 2025PLURPluriN/A-$0.94N/A-$0.94N/A$0.43 million5/13/2025Q1 2025TILInstil Bio-$2.02-$4.32-$2.30-$4.32N/AN/A5/6/2025Q1 2025EPRXEupraxia Pharmaceuticals-$0.19-$0.21-$0.02-$0.21N/AN/A3/27/2025Q4 2024FTLFFitLife Brands$0.22$0.21-$0.01N/AN/AN/A3/20/2025Q4 2024EPRXEupraxia Pharmaceuticals-$0.20-$0.21-$0.01-$0.21N/AN/A3/4/2025Q4 2024TILInstil Bio-$3.75-$1.82+$1.93-$1.82N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AFTLFFitLife BrandsN/AN/AN/AN/AN/APLURPluriN/AN/AN/AN/AN/ATILInstil BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEPRXEupraxia PharmaceuticalsN/A4.174.17FTLFFitLife Brands0.281.500.64PLURPluri4.445.045.04TILInstil Bio0.4712.9012.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEPRXEupraxia PharmaceuticalsN/AFTLFFitLife Brands2.32%PLURPluri16.59%TILInstil Bio60.56%Insider OwnershipCompanyInsider OwnershipEPRXEupraxia PharmaceuticalsN/AFTLFFitLife Brands61.30%PLURPluri10.20%TILInstil Bio47.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEPRXEupraxia Pharmaceuticals2935.85 millionN/AN/AFTLFFitLife Brands209.39 million3.56 millionNot OptionablePLURPluri1507.83 million6.28 millionOptionableTILInstil Bio4106.56 million3.49 millionNo DataPLUR, EPRX, TIL, and FTLF HeadlinesRecent News About These CompaniesInstil Bio appoints Jamie Freedman as Chief Medical OfficerJune 2 at 8:10 PM | msn.comInstil Bio, Inc. Appoints Jamie Freedman, M.D., Ph.D., as Chief Medical Officer to Propel Cancer Therapy DevelopmentJune 2 at 7:19 AM | quiverquant.comInstil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical OfficerJune 2 at 7:00 AM | globenewswire.comInstil Bio to Participate in the 2025 Jefferies Global Healthcare ConferenceMay 30, 2025 | globenewswire.comInstil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?May 29, 2025 | zacks.comWall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to TradeMay 29, 2025 | zacks.comInstil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF SuccessMay 25, 2025 | seekingalpha.comInstil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ...May 25, 2025 | morningstar.comInstil Bio stock price target cut to $105 by H.C. WainwrightMay 24, 2025 | uk.investing.comInstil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in ...May 24, 2025 | seekingalpha.comInstil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in ChicagoMay 23, 2025 | globenewswire.comInstil Bio Shares Jump on Trial Updates for Lung Cancer TreatmentMay 23, 2025 | marketwatch.comInstil Bio shares rise on immunotherapy trial updatesMay 23, 2025 | msn.comInstil Bio shares rise after updates on cancer trialsMay 23, 2025 | seekingalpha.comInstil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025May 22, 2025 | globenewswire.comInstil Bio, Inc. Progresses with Ongoing NSCLC Trials for AXN-2510/IMM2510 and Reports Q1 2025 Financial ResultsMay 13, 2025 | quiverquant.comInstil Bio Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 13, 2025 | globenewswire.comInstil Bio reports Q4 adjusted EPS ($1.08) vs. ($1.26) last yearMarch 4, 2025 | markets.businessinsider.comInstil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 4, 2025 | globenewswire.comInstil Bio: Time To Hop On The Summit Wave?February 24, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 High-Paying Dividend Stocks That Still Have Safe PayoutsBy Chris Markoch | May 27, 2025View 3 High-Paying Dividend Stocks That Still Have Safe Payouts3 Beaten-Down Stocks Trading 50% Below Their 52-Week HighsBy Leo Miller | May 27, 2025View 3 Beaten-Down Stocks Trading 50% Below Their 52-Week HighsDoubt the Market? 3 Stocks to Rideout Fear, Uncertainty and DoubtBy Dan Schmidt | May 26, 2025View Doubt the Market? 3 Stocks to Rideout Fear, Uncertainty and DoubtPalantir: AI Leadership and Rising Analyst ExpectationsBy Chris Markoch | May 20, 2025View Palantir: AI Leadership and Rising Analyst Expectations3 Companies That Just Raised Dividends; 2 to Buy, 1 to AvoidBy Chris Markoch | May 19, 2025View 3 Companies That Just Raised Dividends; 2 to Buy, 1 to AvoidPLUR, EPRX, TIL, and FTLF Company DescriptionsEupraxia Pharmaceuticals NASDAQ:EPRX$3.94 +0.06 (+1.55%) Closing price 06/2/2025 03:59 PM EasternExtended Trading$3.94 0.00 (0.00%) As of 06/2/2025 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.FitLife Brands NASDAQ:FTLF$14.83 +0.19 (+1.30%) As of 06/2/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.Pluri NASDAQ:PLUR$4.49 +0.03 (+0.67%) As of 06/2/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.Instil Bio NASDAQ:TIL$29.65 +2.70 (+10.02%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$32.30 +2.66 (+8.95%) As of 07:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Ulta’s Beautiful Q1 Earnings Report Points to More Gains Ahead Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Chewy Stock Gets a New $7.1 Billion Investor and Analyst Upgrade Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern 3 Stocks With 3% to 9% Yields Just Raised Dividends Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
